Dowpharma sells UK businesses

Dow Chemical has sold its Dowpharma Small Molecules business, along with its Mirfield, West Yorkshire and Cambridge sites, to the European subsidiary of India-based Dr Reddy’s Laboratories.

While the financial details of the contract were not disclosed, the sale includes associated product and process technology, intellectual property and trademarks.

The ownership of the Mirfield and Cambridge facilities will also be transferred to Dr Reddy’s, and employees directly related to the Dowpharma business at the sites will also join the new owners.

The Dowpharma businesses in the US, as well as the Pfenex Expression Technology, are not part of the agreement. Dr Reddy’s, however, does have a non-exclusive license to the Pfenex Expression Technology to support existing biocatalysis development.

Peter Davies, president of Dow’s Designed Polymers and Latex business, said: ‘Dr Reddy’s core operations and capabilities are strongly aligned with the specialty chiral and biocatalysis custom manufacturing business, so it is well equipped to help these businesses reach their full potential. Our priority now is working closely with Dr Reddy’s to continue to ensure a seamless transition for our customers.’

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox